Marilyn Galindo, MD
@marilyngalindomd.bsky.social
Internal and obesity medicine board certified
Obesity Advocate
Hospitalist
Obesity Advocate
Hospitalist
Reposted by Marilyn Galindo, MD
LA fires are a good reminder that the only difference between me and any refugee is luck.
January 8, 2025 at 3:23 PM
LA fires are a good reminder that the only difference between me and any refugee is luck.
It’s crazy that #healthinsurnaces get away with denying basic care. #medsky
January 9, 2025 at 3:11 AM
It’s crazy that #healthinsurnaces get away with denying basic care. #medsky
Reposted by Marilyn Galindo, MD
A systematic review finds that Lilly's retatrutide, a triple agonist GLP-1 still under study, led to the greatest weight loss among drugs in the class--22% at 48 weeks. via @medscape.com
#obesity #weightloss #GLP1 #EliLilly #Medsky #NovoNordisk #semaglutide
#obesity #weightloss #GLP1 #EliLilly #Medsky #NovoNordisk #semaglutide
Retatrutide Produces Greatest Weight Loss
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and investigational agents.
www.medscape.com
January 8, 2025 at 10:49 PM
A systematic review finds that Lilly's retatrutide, a triple agonist GLP-1 still under study, led to the greatest weight loss among drugs in the class--22% at 48 weeks. via @medscape.com
#obesity #weightloss #GLP1 #EliLilly #Medsky #NovoNordisk #semaglutide
#obesity #weightloss #GLP1 #EliLilly #Medsky #NovoNordisk #semaglutide
Medicare is now covering Zepbound for people with sleep apnea!
January 9, 2025 at 2:58 AM
Medicare is now covering Zepbound for people with sleep apnea!